| Literature DB >> 34917668 |
Serenella Silvestri1, Elisa Rampacci1, Valentina Stefanetti1, Michele Trotta2, Caterina Fani2, Lucia Levorato3, Chiara Brachelente1, Fabrizio Passamonti1.
Abstract
The indiscriminate use of first-line drugs contributed to the spread of resistant bacteria, a major concern for both human and veterinary medicine. Methicillin resistance is acquired through the mecA gene, which encodes for the PBP2a protein and lends the resistance to β-lactams. Verifying the correspondence between gene harboring and protein expression and accelerating methicillin resistance diagnosis is critical to improve the management of antimicrobial administration and to reduce the spread of drug resistances. We tested the applicability of immunofluorescence targeting PBP2a protein to identify a new potential methicillin resistance screening test, ancillary to conventional culture methods. We collected 26 clinical Staphylococcus pseudintermedius (SP) isolates: 25 from canine pyoderma and 1 from dermatitis in a dog owner. SP is one of the most important etiological agents in canine pyoderma and can harbor the mecA gene. We performed PCR for mecA gene detection, broth microdilution (BMD) for phenotypic methicillin resistance, and immunofluorescence targeting PBP2a protein. Compared to the PCR as the gold standard, immunofluorescence showed an apparent prevalence of 34.6% vs. a true prevalence of 53.8%, with 100% specificity, 64.3% sensitivity, and 80.8% diagnostic accuracy. PBP2a expression showed isolate-dependent variability: in some isolates, most of the bacterial cells showed an intense and clearly membranous pattern, while in others only a few of them could be detected. Performing the assay in duplicate improved the diagnostic accuracy. Since the mecA gene is shared among the members of the Staphylococcus genus, the test can be applied to identify methicillin resistance independently from the staphylococcal species, both in human and animal samples. Being a rapid and easy method and providing the unique possibility to study the expression of PBP2a by directly visualizing the morphology, it could represent a new interesting tool for both research and diagnostics. To accelerate methicillin resistance diagnosis, it would be worth further testing of its performance on cytological samples.Entities:
Keywords: Staphylococcus pseudintermedius; antimicrobial drug resistance; dogs; fluorescent antibody technique; humans; methicillin resistance; penicillin-binding protein 2a; pyoderma
Year: 2021 PMID: 34917668 PMCID: PMC8669817 DOI: 10.3389/fvets.2021.740934
Source DB: PubMed Journal: Front Vet Sci ISSN: 2297-1769
Results of methicillin resistance investigation in the SP isolates and their MDR status.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| Pos ctr | >32 | R | + | + | + |
| Neg ctr | ≤ 0.125 | S | − | − | − |
| SP01 | ≤ 0.125 | S | − | − | − |
| SP02 | ≤ 0.125 | S | − | − | − |
| SP03 | ≤ 0.125 | S | − | − | − |
| SP04 | >32 | R | + | + | + |
| SP05 | >32 | R | + | + | + |
| SP06 | >32 | R | + | + | + |
| SP07 | >32 | R | + | + | + |
| SP08 | ≤ 0.125 | S | − | − | − |
| SP09 | 8 | R | + | + | + |
| SP10 | ≤ 0.125 | S | − | − | − |
| SP11 | 1 | R | − | − | + |
| SP12 | >32 | R | + | + | + |
| SP13 | >32 | R | + | − | + |
| SP14 | 1 | R | + | − | − |
| SP15 | 0.25 | S | − | − | − |
| SP16 | ≤ 0.125 | S | − | − | − |
| SP17 | >32 | R | + | + | + |
| SP18 | ≤ 0.125 | S | − | − | − |
| SP19 | >32 | R | + | − | + |
| SP20 | ≤ 0.125 | S | − | − | − |
| SP21 | >32 | R | + | + | + |
| SP22 | 0.5 | R | + | − | − |
| SP23 | 1 | R | + | − | ND |
| SP24 | ≤ 0.125 | S | − | − | − |
R, resistant; S, sensitive; ND, not determined; SP24, human isolate.
Results of BMD were previously published (.
The immunofluorescence (IF) results after 2 replicates are shown.
Figure 1Methicillin resistance and multi-drug resistance in SP isolates. (A) Proportions of multidrug-resistant (MDR) SP and not MDR SP. R, resistant; S, sensitive. (B) Proportions of methicillin-resistant SP (MRSP) and methicillin-sensitive SP (MSSP). (C) Proportions of MRSP and MSSP in MDR SP and not MDR SP.
Figure 2Immunofluorescence targeting PBP2a protein in SP, showing isolate-dependent variability in PBP2a expression level. (A) Negative control. Insert: a cluster of SP whose cell walls stained negative and only the nucleoid can be seen (blue). (B) A cluster of SP clearly expressing PBP2a protein (green) is shown; the majority of SP does not express the protein. Insert: a magnification of cell walls staining positive, with a well-defined membranous pattern. (C) Several SP, both in clusters and sparse, stained positive, while a large proportion of them is negative. Insert: bacteria with cell wall expression of PBP2a protein. (D) Most of the SP showed positive cell walls. Insert: a cluster of bacteria where most of them have distinct positivity of the cell walls, together with other negative bacteria where only the nucleoid is stained. Blue: DAPI; Green: Alexa Fluor® 488.
Measures of diagnostic test accuracy.
|
|
|
|
|---|---|---|
| Apparent prevalence | 34.6% | 17.2–55.7% |
| True prevalence | 53.8% | 33.4–73.4% |
| Sensitivity | 64.3% | 35.1–87.2% |
| Specificity | 100% | 64.0–100% |
| Positive predictive value | 100% | 55.5–100% |
| Negative predictive value | 70.6% | 44.0–89.7% |
| Likelyhood ratio for positive test | inf | NA |
| Likelyhood ratio for negative test | 0.357 | 0.177–0.721 |
| Diagnostic accuracy | 80.8% | 60.6–93.4% |
CI.
inf, infinity; NA, non applicable.
Figure 3Proportions of mecA+ and mecA− SP tested by PCR among cases with detected and not PBP2a expression by immunofluorescence assay.